Vergara, Maxcryl Klenmae M.
HRN: 21-91-25 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/19/2022
CO-AMOXICLAV 625MG (TAB)
10/19/2022
10/26/2022
ORAL
625mg/tab
BID
S/P 2° RMLE With Episiotomy & Episiorrhaphy
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueReproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes